Research graph
References from Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators. Local targets link to admitted publications; unresolved targets remain external evidence.
Molecular genetic studies of ADHD: 1991 to 2004
2004 · External reference
10.1038/sj.mp.4001048 · 2002 · Admitted local publication
Serotonergic and Adrenergic Neuroreceptor Manipulation Ameliorates Core Symptoms of ADHD through Modulating Dopaminergic Receptors in Spontaneously Hypertensive Rats
10.3390/ijms25042300 · 2024 · External reference
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs
10.1016/s0014-2999(02)02074-5 · 2002 · External reference
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
10.1124/jpet.110.167346 · 2010 · External reference
Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist
10.1023/b:card.0000015857.96371.43 · 2003 · External reference
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
10.1007/bf02245606 · 1996 · External reference
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs
10.1038/sj.npp.1300027 · 2003 · External reference
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
10.1177/0269881107082944 · 2009 · External reference
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors
10.1007/s00210-004-0951-4 · 2004 · External reference
Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist
10.1124/jpet.104.066688 · 2004 · External reference
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol
10.1016/s0022-3565(24)37731-6 · 1998 · External reference
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors
10.1016/s0022-3565(24)38891-3 · 2000 · External reference
A brief history of antidepressant drug development: from tricyclics to beyond ketamine
10.1017/neu.2017.39 · 2018 · External reference
Hallucinogens
10.1016/j.pharmthera.2003.11.002 · 2004 · External reference
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
10.1177/2045125314527985 · 2014 · External reference
Psychedelics
10.1124/pr.115.011478 · 2016 · External reference
Psychedelic-inspired drug discovery using an engineered biosensor
10.1016/j.cell.2021.03.043 · 2021 · External reference
A non-hallucinogenic psychedelic analogue with therapeutic potential
10.1038/s41586-020-3008-z · 2021 · External reference
Structure-based discovery of nonhallucinogenic psychedelic analogs
10.1126/science.abl8615 · 2022 · External reference
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
10.1038/s41586-022-05258-z · 2022 · External reference
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo
10.1523/jneurosci.1665-10.2010 · 2010 · External reference
Structural pharmacology and therapeutic potential of 5-methoxytryptamines
10.1038/s41586-024-07403-2 · 2024 · External reference
The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors
10.1016/s0091-3057(99)00178-1 · 2000 · External reference
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
10.1038/s41386-024-01794-6 · 2024 · External reference
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
10.1038/s41593-023-01316-5 · 2023 · External reference
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
2025 · External reference
Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
10.1038/s41586-025-08813-6 · 2025 · External reference
The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats
10.1007/s00213-006-0566-1 · 2006 · External reference
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential
10.1038/s41467-023-44016-1 · 2023 · External reference
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
10.1016/j.neuropharm.2019.107933 · 2020 · External reference
[19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors
10.1016/s1043-9471(05)80049-7 · 1995 · External reference
The Molecular Basis of G Protein-Coupled Receptor Activation
10.1146/annurev-biochem-060614-033910 · 2018 · External reference
Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor
10.1124/mol.107.039255 · 2007 · External reference
“Selective” serotonin 5-HT2A receptor antagonists
10.1016/j.bcp.2022.115028 · 2022 · External reference
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
2020 · External reference
The role of ligands on the equilibria between functional states of a G protein-coupled receptor
10.1021/ja404305k · 2013 · External reference
Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor
10.1021/acs.jcim.1c00826 · 2021 · External reference
Magic angle spinning NMR of G protein-coupled receptors
10.1016/j.pnmrs.2021.10.002 · 2022 · External reference
Activation mechanism of the β2-adrenergic receptor
10.1073/pnas.1110499108 · 2011 · External reference
Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism
2023 · External reference
Energy Landscapes Reveal Agonist Control of G Protein-Coupled Receptor Activation via Microswitches
10.1021/acs.biochem.9b00842 · 2020 · External reference
The Protein Data Bank
10.1093/nar/28.1.235 · 2000 · External reference
CHARMM-GUI: a web-based graphical user interface for CHARMM
10.1002/jcc.20945 · 2008 · External reference
β 2 -Adrenergic Receptor Conformational Response to Fusion Protein in the Third Intracellular Loop
10.1016/j.str.2016.09.015 · 2016 · External reference
CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues
10.1016/bs.apcsb.2014.06.002 · 2014 · External reference
CHARMM-GUI PDB Reader and Manipulator: Covalent Ligand Modeling and Simulation
10.1016/j.jmb.2024.168554 · 2024 · External reference
CHARMM-GUI PDB Manipulator: Various PDB Structural Modifications for Biomolecular Modeling and Simulation
10.1016/j.jmb.2023.167995 · 2023 · External reference
CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field
10.1021/acs.jctc.5b00935 · 2016 · External reference
Mini-G proteins: Novel tools for studying GPCRs in their active conformation
10.1371/journal.pone.0175642 · 2017 · External reference
CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules
10.1002/jcc.24829 · 2017 · External reference
CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids
10.1021/acs.jcim.1c00770 · 2021 · External reference
CHARMM-GUI Membrane Builder: Past, Current, and Future Developments and Applications
10.1021/acs.jctc.2c01246 · 2023 · External reference
Automated builder and database of protein/membrane complexes for molecular dynamics simulations
2007 · External reference
CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes
10.1016/j.bpj.2009.04.013 · 2009 · External reference
CHARMM-GUI Membrane Builder toward realistic biological membrane simulations
10.1002/jcc.23702 · 2014 · External reference
OPM: orientations of proteins in membranes database
10.1093/bioinformatics/btk023 · 2006 · External reference
Neuronal Membrane Lipids – Their Role in the Synaptic Vesicle Cycle
10.1007/978-0-387-30378-9_9 · 2009 · External reference
Open Babel: An open chemical toolbox
10.1186/1758-2946-3-33 · 2011 · External reference
Scalable molecular dynamics on CPU and GPU architectures with NAMD
10.1063/5.0014475 · 2020 · External reference
CHARMM: the biomolecular simulation program
10.1002/jcc.21287 · 2009 · External reference
VMD: visual molecular dynamics
10.1016/0263-7855(96)00018-5 · 1996 · External reference
MDAnalysis: a toolkit for the analysis of molecular dynamics simulations
10.1002/jcc.21787 · 2011 · External reference
Scikit-learn: Machine Learning in Python
2011 · External reference
SciPy 1.0: fundamental algorithms for scientific computing in Python
10.1038/s41592-019-0686-2 · 2020 · External reference
Structure and function of an irreversible agonist-β(2) adrenoceptor complex
10.1038/nature09665 · 2011 · External reference
The structural diversity of psychedelic drug actions revealed
10.1038/s41467-025-57956-7 · 2025 · External reference
The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH
10.1016/j.bcp.2020.113979 · 2020 · External reference
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists
10.1021/acs.jmedchem.2c00702 · 2022 · External reference
Ligand-Free Signaling of G Protein Coupled Receptors: Addressing Unresolved questions with Antagonist Probes and Genomics
10.18103/mra.v12i9.5666 · 2024 · External reference
Less is more? A review of psilocybin microdosing
10.1177/02698811241278769 · 2024 · External reference
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
10.1038/s41380-023-02280-z · 2023 · External reference
